| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cancer Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064
1 To whom requests for reprints may be addressed, at Abbott Laboratories, Global Pharmaceutical Research and Development, Department 47B, AP10/114, 100 Abbott Park Road, Abbott Park, IL 60064. Phone: (847) 935-5182 (Z. C.) or (847) 938-4857 (H. Z.); Fax: (847) 935-7551; E-mail: zehan.chen{at}abbott.com (Z. C.) or haiying.zhang{at}abbott.com (H. Z.)
Mammalian Chk1 is an essential kinase for embryonic development and plays an important role in the cellular response to DNA damage. However, it remains unclear whether inhibition of Chk1 induces apoptosis in somatic cells. The uncertainty has become a critical issue for rationale design of Chk1 mechanism-based anticancer drugs. Here we show that Chk1 small interfering RNA (siRNA) effectively eliminates Chk1 protein expression without altering the cell cycle profile or inducing apoptosis in various human cancer cell lines under normal conditions. In the presence of DNA-damaging agents, however, Chk1 siRNA alone is sufficient to abrogate the DNA damage-induced G2 checkpoint and significantly enhance apoptosis. Cell cycle kinetic profiles show that abrogation of G2 arrest is mediated through shortening of the checkpoint. We also demonstrate that Chk1 siRNA enhances DNA damage-induced apoptosis in p53-deficient cancer cell lines and augments the growth inhibition conferred by DNA-damaging agents. These findings imply that Chk1 inhibitors will have low cytotoxicity on their own and can enhance the efficacy of DNA-damaging drugs.
This article has been cited by other articles:
|
|
 |
|
  S. D. Zabludoff, C. Deng, M. R. Grondine, A. M. Sheehy, S. Ashwell, B. L. Caleb, S. Green, H. R. Haye, C. L. Horn, J. W. Janetka, et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies Mol. Cancer Ther., September 1, 2008; 7(9): 2955 - 2966. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ganzinelli, L. Carrassa, F. Crippa, M. Tavecchio, M. Broggini, and G. Damia Checkpoint Kinase 1 Down-Regulation by an Inducible Small Interfering RNA Expression System Sensitized In vivo Tumors to Treatment with 5-Fluorouracil Clin. Cancer Res., August 15, 2008; 14(16): 5131 - 5141. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Blasina, J. Hallin, E. Chen, M. E. Arango, E. Kraynov, J. Register, S. Grant, S. Ninkovic, P. Chen, T. Nichols, et al. Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1 Mol. Cancer Ther., August 1, 2008; 7(8): 2394 - 2404. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ashwell and S. Zabludoff DNA Damage Detection and Repair Pathways--Recent Advances with Inhibitors of Checkpoint Kinases in Cancer Therapy Clin. Cancer Res., July 1, 2008; 14(13): 4032 - 4037. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Scorah, M.-Q. Dong, J. R. Yates III, M. Scott, D. Gillespie, and C. H. McGowan A Conserved Proliferating Cell Nuclear Antigen-interacting Protein Sequence in Chk1 Is Required for Checkpoint Function J. Biol. Chem., June 20, 2008; 283(25): 17250 - 17259. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J.H. Arlander, B. T. Greene, C. L. Innes, and R. S. Paules DNA Protein Kinase Dependent G2 Checkpoint Revealed following Knockdown of Ataxia-Telangiectasia Mutated in Human Mammary Epithelial Cells Cancer Res., January 1, 2008; 68(1): 89 - 97. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-D. Ha, D. Ng, S. L. Pelech, and S. O. Kim Critical Role of the Phosphatidylinositol 3-Kinase/Akt/Glycogen Synthase Kinase-3 Signaling Pathway in Recovery from Anthrax Lethal Toxin-induced Cell Cycle Arrest and MEK Cleavage in Macrophages J. Biol. Chem., December 14, 2007; 282(50): 36230 - 36239. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Dotiwala, J. Haase, A. Arbel-Eden, K. Bloom, and J. E. Haber The yeast DNA damage checkpoint proteins control a cytoplasmic response to DNA damage PNAS, July 3, 2007; 104(27): 11358 - 11363. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Curry, L. L. Reed, E. Broude, T. E. Golde, L. Miele, and K. E. Foreman Notch inhibition in Kaposi's sarcoma tumor cells leads to mitotic catastrophe through nuclear factor-{kappa}B signaling Mol. Cancer Ther., July 1, 2007; 6(7): 1983 - 1992. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-J. Jang, J.-H. Ji, Y.-C. Choi, C. J. Ryu, and S.-Y. Ko Regulation of Polo-like Kinase 1 by DNA Damage in Mitosis: INHIBITION OF MITOTIC PLK-1 BY PROTEIN PHOSPHATASE 2A J. Biol. Chem., January 26, 2007; 282(4): 2473 - 2482. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Comess, J. D. Trumbull, C. Park, Z. Chen, R. A. Judge, M. J. Voorbach, M. Coen, L. Gao, H. Tang, P. Kovar, et al. Kinase Drug Discovery by Affinity Selection/Mass Spectrometry (ASMS): Application to DNA Damage Checkpoint Kinase Chk1 J Biomol Screen, October 1, 2006; 11(7): 755 - 764. [Abstract] [PDF]
|
|
|
|
|
|
J. Tang, R. L. Erikson, and X. Liu Checkpoint kinase 1 (Chk1) is required for mitotic progression through negative regulation of polo-like kinase 1 (Plk1) PNAS, August 8, 2006; 103(32): 11964 - 11969. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Xiao, J. Xue, T. J. Sowin, and H. Zhang Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy. Mol. Cancer Ther., August 1, 2006; 5(8): 1935 - 1943. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Bhonde, M.-L. Hanski, J. Budczies, M. Cao, B. Gillissen, D. Moorthy, F. Simonetta, H. Scherubl, M. Truss, C. Hagemeier, et al. DNA Damage-induced Expression of p53 Suppresses Mitotic Checkpoint Kinase hMps1: THE LACK OF THIS SUPPRESSION IN p53MUT CELLS CONTRIBUTES TO APOPTOSIS J. Biol. Chem., March 31, 2006; 281(13): 8675 - 8685. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Chen, P. J. Merta, N.-H. Lin, S. K. Tahir, P. Kovar, H. L. Sham, and H. Zhang A-432411, a novel indolinone compound that disrupts spindle pole formation and inhibits human cancer cell growth Mol. Cancer Ther., April 1, 2005; 4(4): 562 - 568. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Wang, T. Wiltshire, Y. Wang, C. Mikell, J. Burks, C. Cunningham, E. S. Van Laar, S. J. Waters, E. Reed, and W. Wang ATM-dependent CHK2 Activation Induced by Anticancer Agent, Irofulven J. Biol. Chem., September 17, 2004; 279(38): 39584 - 39592. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kawabe G2 checkpoint abrogators as anticancer drugs Mol. Cancer Ther., April 1, 2004; 3(4): 513 - 519. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
